XNAS · Healthcare · Biotechnology
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.89 | -0.99 | -11.24% | $0 | ❌ Miss | -1.36% | +20.18% | — |
| 2026-03-23 | Q4 2025 | -0.82 | -0.81 | +1.22% | $0 | ✅ Beat | -1.54% | -10.46% | +36.04% |
| 2025-11-13 |
| Q3 2025 |
| -0.81 |
| -0.75 |
| +7.41% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -0.57 | -0.66 | -15.79% | $0 | ❌ Miss | -10.36% | -13.66% | -23.30% |
Showing last 4 quarters.